PharVision Advisers’s Newmark Group NMRK Stock Holding History

PharVision Advisers’s Portfolio NMRK Stock Details NMRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,964	Closed	-$277K	–	465
2025 Q4	$277K	Buy	+15,964	New	+$280K	0.14%	325

Other funds holding NMRK

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PharVision Advisers's NMRK Position: Q1 2026 in Review

PharVision Advisers sold out of Newmark Group (NMRK) in Q1 2026, closing a stake of 15,964 shares — an estimated $277K sold.

PharVision Advisers first reported a position in NMRK in Q4 2025 and held it in 1 quarter. The position peaked at $277K in Q4 2025. 307 funds tracked by Wall St. Rank hold NMRK as of Q1 2026.

PharVision Advisers reported no remaining Newmark Group position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 15,964 Newmark Group shares in Q1 2026, an estimated $277K.
PharVision Advisers first reported a position in Newmark Group in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Newmark Group position peaked at $277K in Q4 2025.
307 funds tracked by Wall St. Rank held Newmark Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.